Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Selective Wee1 Inhibitors Led to Antitumor Activity In Vitro and Correlated with Myelosuppression
Satenig Guler, Maria C. DiPoto, Alejandro Crespo, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 5, pp. 566-576
Open Access | Times Cited: 11

Showing 11 citing articles:

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications
Yvette Drew, Frank T. Zenke, Nicola J. Curtin
Nature Reviews Drug Discovery (2024) Vol. 24, Iss. 1, pp. 19-39
Closed Access | Times Cited: 8
Synthetic and Medicinal Chemistry Approaches Toward WEE1 Kinase Inhibitors and Its Degraders
Vidya Jyothi Alli, Pawan Kumar Yadav, V. Suresh, et al.
ACS Omega (2023) Vol. 8, Iss. 23, pp. 20196-20233
Open Access | Times Cited: 16
Discovery of WEE1 Kinase Inhibitors with Potent Activity against Patient-Derived, Metastatic Colorectal Cancer Organoids
Joel L. Syphers, Josephine A. Wright, Shen Liu, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Integrated AI and machine learning pipeline identifies novel WEE1 kinase inhibitors for targeted cancer therapy
Jaikanth Chandrasekaran, D. Gopal, Lokesh Vishwa Sureshkumar, et al.
Molecular Diversity (2025)
Closed Access
Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors
Chi Zhang, Ke Peng, Qing Liu, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 193, pp. 104233-104233
Closed Access | Times Cited: 8
Advanced Design, Synthesis, and Evaluation of Highly Selective Wee1 Inhibitors: Enhancing Pharmacokinetics and Antitumor Efficacy
Yong Wang, Xu Chunyue, Yiqing Jiang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 12, pp. 9927-9949
Closed Access | Times Cited: 2
Structure-Based Drug Design of 2-Amino-[1,1′-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1-Amplified Breast Cancer
Chaofan Wang, Yan Fang, Zi-Qin Zhou, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 17, pp. 15816-15836
Closed Access | Times Cited: 2
Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer
Shaobin Wang, Chao Wang, Tingting Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 67, Iss. 1, pp. 420-432
Closed Access | Times Cited: 6
Discovery of pyrrolopyrimidinone derivatives as potent PKMYT1 inhibitors for the treatment of cancer
Chao Wang, Shaobin Wang, Fanye Meng, et al.
European Journal of Medicinal Chemistry (2024) Vol. 281, pp. 117025-117025
Closed Access
CGPDTA: An Explainable Transfer Learning‐Based Predictor With Molecule Substructure Graph for Drug‐Target Binding Affinity
Qing Fan, Yingxu Liu, Simeng Zhang, et al.
Journal of Computational Chemistry (2024) Vol. 46, Iss. 1
Closed Access
Synthesis and biological evaluation of (2‐aminosulfonylpyridin‐6‐yl)pyrazolopyrimidinone derivatives as Wee1 inhibitors for cancer treatment
Yeon Ju Kim, M. JUNG, Ju Yeong Lee, et al.
Bulletin of the Korean Chemical Society (2023) Vol. 45, Iss. 1, pp. 60-66
Open Access | Times Cited: 1
Page 1

Scroll to top